Meetings & Webinars

CiPA Meetings

NEW! CiPA Update Meeting 2, December 6, 2016. Slides now posted. View them here.

CiPA Update Meeting 1, December 11, 2014. View the synopsis here and the available presentations here.

CiPA Kick-Off Meeting, July 23, 2013. View the agenda and presentations here.

 

Related Meetings & Webinars

BioPharma Research Council Webinar. Focus on the CiPA paradigm: Update from the front lines. Presented by Dr. Bernard Fermini, Pfizer Inc, June 2, 2016.

GE Cell Technologies, Assessment of the potential for drugs to cause cardiac arrhythmias: Evolving response to a problem in drug development: presented by Dr. Norman Stockbridge, US FDA, 11/28/2012

CSPS, Assessment of the potential for drugs to cause cardiac arrhythmias (In Chinese): presented by Dr. Norman Stockbridge, US FDA,  6/5/2013

DIA Webinar, The New Paradigm: Next Steps: presented by Dr. Norman Stockbridge, US FDA,  10/30/2013

Stanford University, Drug Safety Cultural, Scientific, and Engineering Issues: presnted by Dr. Norman Stockbrige, US FDA,  12/2/2013

Pacific Coast Statisticians and Pharmacometricians Innovation Conference, Beyond QT—The Comprehensive in Vitro Proarrhythmia Assay: presented by Dr. Norman Stockbridge, US FDA,  2/26/2014

DIA Annual Meeting, Implementation and Implications of Non-Clinical Proarrhythmia Assessment: presented by Dr. Norman Stockbridge, US FDA,  6/13/2014

DIA 2014 Annual Meeting, The Need for a new paradigm to assess proarrhythmic effects of drugs: presented by Dr. Philip Sager,  6/14/2014

AACP, Proarrhythmic Assessment of Drugs: Need for a new paradigm: presented by Dr. Philip Sager,  7/8/2014

Safety Pharmacology Society, Comprehensive in vitro Proarrhythmia Assay: CIPA: presented by Dr. Norman Stockbridge, US FDA, 9/11/2014

American College of Clinical Pharmacology (ACCP), The Comprehensive* in Vitro Proarrhythmia Assay: presented by Dr. Norman Stockbridge, US FDA, 9/13/2014

Regulatory Affairs Professionals Society (RAPS), Evolution of testing pharmaceuticals for proarrhythmic potential: An example of applied regulatory science: presented by Dr. Norman Stockbridge, US FDA,  9/28/2014

DIA-Japan, Comprehensive in vitro Proarrhythmia Assay: CIPA: presented by Dr. Norman Stockbridge, US FDA,  9/28/2014

DIA Japan, The New Paradigm for Proarrhythmia Assessment without the TQT Study: presented by Dr. Philip Sager,  10/22/2014

American Association of Pharmaceutical Scientists, Current and future assessment of cardiotoxicity beyond the TQT: presented by Dr. Norman Stockbridge, US FDA,  11/3/2014

ACT Annual Meeting, Proarrhythmic Assessment of Drugs: The Need for a New Paradigm: presented by Dr. Philip Sager,  11/8/2014

American College of Toxicology, A regulatory perspective on assessment of cardiotoxicity Beyond QTc: presented by Dr. Norman Stockbridge, US FDA,  11/10/2014

DIA-China, Shifting Gears to Non-Clinical Pro-Arrhythmia Models: Rationale and Scope of the Proposed CiPA Paradigm: presented by Dr. Norman Stockbridge, US FDA,  11/22/2014

CBI Drug Safety Meeting, The In Vitro Evaluation of ProA Risk - The Evolving CIPA Paradigm: presented by Dr. Gary Gintant, AbbVie,  2/9/2015

CSRC Annual Meeting, Current Status, Opportunities and Challenges: presented by Dr. Hugo Vargas, Amgen,  2/18/2015

American Society for Clinical Pharmacology and Therapeutics, Emerging approaches to assess proarrhythmic risk: Regulatory perspective: presented by Dr. Norman Stockbridge, US FDA,  3/6/2015